Estrella Immunopharma【ESLA】銘柄情報

Estrella Immunopharma Inc (ESLA) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.06

( -1.85% )

買値

1.04

売値

1.16

出来高

22,383

1.04 日の範囲 1.10

0.78 52 週間の範囲 3.15

時価総額

45.616M

前日終値

1.08

始値

1.07

時刻

1.0401

最終取引時間

財務取引量

US$ 23,954

VWAP

1.0702

平均取引量 (3 か月)

US$ 84,297

発行済株式数

43,034,228

配当利回り

PER

-3.06

1 株当たり利益 (EPS)

-0.35

歳入

純利益

-13.25M

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104,... Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.estrellabio.com

本社

Emeryville, United States

設立

2026

Estrella Immunopharma Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ESLA. The last closing price for Estrella Immunopharma was US$1.08. Over the last year, Estrella Immunopharma shares have traded in a share price range of US$ 0.78 to US$ 3.15.

Estrella Immunopharma currently has 43,034,228 shares in issue. The market capitalisation of Estrella Immunopharma is US$45.62 million. Estrella Immunopharma has a price to earnings ratio (PE ratio) of -3.06.

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and...

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and...

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma, Inc. (Nasdaq: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and...

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted...

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS...

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

An independent Data Safety Monitoring Board (DSMB) confirms EB103’s favorable safety profile with no treatment-related serious adverse events...

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and...

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and...

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and...

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.09	-7.82608695652	1.15	1.2097	1.02	34027	1.11376154	CS
4	-0.14	-11.6666666667	1.2	1.24	1.02	38188	1.12708849	CS
12	-0.01	-0.934579439252	1.07	2.1	0.97	86088	1.5089798	CS
26	-0.73	-40.782122905	1.79	2.1	0.8936	129862	1.37288873	CS
52	0.03	2.91262135922	1.03	3.15	0.78	141229	1.71188016	CS
156	-4.15	-79.6545105566	5.21	5.62	0.63	112405	1.49772193	CS
260	-4.15	-79.6545105566	5.21	5.62	0.63	112405	1.49772193	CS

ESLA - Frequently Asked Questions (FAQ)

What is the current Estrella Immunopharma Inc share price?

The current share price of Estrella Immunopharma Inc is US$ 1.06

How many Estrella Immunopharma Inc shares are in issue?

Estrella Immunopharma Inc has 43,034,228 shares in issue

What is the market cap of Estrella Immunopharma Inc?

The market capitalisation of Estrella Immunopharma Inc is USD 45.62M

What is the 1 year trading range for Estrella Immunopharma Inc share price?

Estrella Immunopharma Inc has traded in the range of US$ 0.78 to US$ 3.15 during the past year

What is the PE ratio of Estrella Immunopharma Inc?

The price to earnings ratio of Estrella Immunopharma Inc is -3.06

What is the registered address of Estrella Immunopharma Inc?

The registered address for Estrella Immunopharma Inc is 5858 Horton Street, EmeryVille, California, 94608

What is the Estrella Immunopharma Inc website address?

The website address for Estrella Immunopharma Inc is www.estrellabio.com

Which industry sector does Estrella Immunopharma Inc operate in?

Estrella Immunopharma Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Estrella Immunopharma Inc (ESLA)

Estrella Immunopharma Inc (ESLA) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Estrella Immunopharma Inc について

ESLA 最新ニュース

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma Shares Gain as CD19 Cancer Therapy Progresses Into Phase II

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

ESLA - Frequently Asked Questions (FAQ)

ESLA 取引

ESLA Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する